# Captain T Cell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/captain-t-cell

- Industry: Biotechnology
- Headquarters: Berlin, Germany
- Website: www.captaintcell.com
- Total disclosed funding: $9.1M
- Latest round: Series A (Nov 2, 2025)
- Investors on record: 7

## About

Founded in 2019 as a spin-off from Max Delbrück Center, Berlin, and based in Berlin, Germany, Captain T Cell GmbH operates as a biotechnology research company that develops efficacy-enhanced T-cell therapies against solid tumors. As of 2025, Felix Lorenz operates as CEO of the company. In November 2025, Captain T Cell GmbH raised Series A funding co-led by Springboard Health Angels and Pluton Asset Holding AG, with participation from Sintra and CFH Management, i&i Bio, Hil-Invent GmbH, and Brandenburg Kapital also participated in the round. The round was part of a larger EUR 20 million equity and grant funding.

Captain T Cell GmbH creates T-cell therapies aimed at persistent solid tumors that do not respond to current treatments. The company provides the TCR-ALLO platform, a novel allogeneic solution that allows for off-the-shelf treatments for different cancers, presenting new options for difficult-to-treat cancer cases.

The company intends to use the November 2025 funding to start clinical trials for its main TCR-T therapy and to develop its off-the-shelf TCR-T program for future testing.

## Funding rounds

- Series A, Nov 2, 2025 — CFH Management, Brandenburg Kapital, Hil-Invent GmbH, i&i Bio, Springboard Health Angels, Sintra, Pluton Asset Holding AG
- Seed, Nov 10, 2023, $9.1M — Brandenburg Kapital, Hil-Invent GmbH, i&i Bio

## Investors

- Brandenburg Kapital (https://capitalatlas.ai/funds/brandenburg-kapital) — Seed, Series A
- Hil-Invent GmbH — Seed, Series A
- i&i Bio (https://capitalatlas.ai/funds/i-i-bio) — Seed, Series A
- CFH Management (https://capitalatlas.ai/funds/cfh-management) — Series A
- Springboard Health Angels — Series A
- Sintra — Series A
- Pluton Asset Holding AG — Series A